Seizure Incidence in Psychopharmacological Clinical Trials: An Analysis of Food and Drug Administration (FDA) Summary Basis of Approval Reports

2007/01/17 by Kenneth Alper, Kelly A. Schwartz, Kelly Schwartz +2 · 522 citations
Medicine · #Alprazolam #Anticonvulsant #Anxiety #Bupropion #Clinical trial #Electroconvulsive Therapy Studies #Epilepsy #Epilepsy research and treatment #Incidence (geometry) #Internal medicine #Medicine #Olanzapine #Placebo #Population #Psychiatry #Quetiapine #Schizophrenia (object-oriented programming) #Schizophrenia research and treatment #Seizure threshold

paper · doi:10.1016/j.biopsych.2006.09.023

published in Biological Psychiatry 62(4), 345-354 (Elsevier BV)

openalex publication_date 2007/01/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Cited by

• Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans
• The 5-HT 1A receptor and 5-HT transporter in temporal lobe epilepsy
• Areas of research priorities in epilepsy: A position paper of the European Reference Network for Rare and Complex Epilepsies, EpiCARE
• Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines
• Psychiatric comorbidities in epilepsy
• Psychological treatments for people with epilepsy
• Depression and epilepsy: Epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence
• Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan
• Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy
• Antidepressants
• Early life stress as an influence on limbic epilepsy: an hypothesis whose time has come? [europepmc]
• Depression in temporal lobe epilepsy: a review of prevalence, clinical features, and management considerations. [europepmc]
• The expanding evidence base for rTMS treatment of depression. [europepmc]
• The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy. [europepmc]
• Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2). [europepmc]
• Mood disorders after TBI. [europepmc]
• Antidepressants for people with epilepsy and depression. [europepmc]
• A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia. [europepmc]
• The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. [europepmc]
• Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. [europepmc]
• Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs. [europepmc]
• Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. [europepmc]
• Psychological treatments for people with epilepsy. [europepmc]
• Lorcaserin therapy for severe epilepsy of childhood onset: A case series. [europepmc]
• Bidirectional relations among common psychiatric and neurologic comorbidities and epilepsy: Do they have an impact on the course of the seizure disorder? [europepmc]
• Designer receptor technology for the treatment of epilepsy. [europepmc]
• Treatment of psychoses in patients with epilepsy: an update. [europepmc]
• Circuits generating secondarily generalized seizures. [europepmc]
• Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children. [europepmc]
• Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. [europepmc]
• Psychiatric Comorbidities in People With Epilepsy. [europepmc]
• Antidepressants for people with epilepsy and depression. [europepmc]
• Temporal Lobe Epilepsy and Psychiatric Comorbidity. [europepmc]
• Parvalbumin Role in Epilepsy and Psychiatric Comorbidities: From Mechanism to Intervention. [europepmc]
• Reactivation of Early-Life Stress-Sensitive Neuronal Ensembles Contributes to Lifelong Stress Hypersensitivity. [europepmc]